Weiner LM - Search Results

1

Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma.

Cohen SJ, Alpaugh RK, Palazzo I, Meropol NJ, Rogatko A, Xu Z, Hoffman JP, Weiner LM, Cheng JD. Cohen SJ, et al. Among authors: weiner lm. Pancreas. 2008 Aug;37(2):154-8. doi: 10.1097/MPA.0b013e31816618ce. Pancreas. 2008. PMID: 18665076

2

Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.

Weiner LM, Clark JI, Davey M, Li WS, Garcia de Palazzo I, Ring DB, Alpaugh RK. Weiner LM, et al. Cancer Res. 1995 Oct 15;55(20):4586-93. Cancer Res. 1995. PMID: 7553634 Clinical Trial.

3

CD16+ monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor.

Saleh MN, Goldman SJ, LoBuglio AF, Beall AC, Sabio H, McCord MC, Minasian L, Alpaugh RK, Weiner LM, Munn DH. Saleh MN, et al. Among authors: weiner lm. Blood. 1995 May 15;85(10):2910-7. Blood. 1995. PMID: 7742551 Free article. Clinical Trial.

4

Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer.

Redei I, Green F, Hoffman JP, Weiner LM, Scher R, O'Dwyer PJ. Redei I, et al. Among authors: weiner lm. Invest New Drugs. 1994;12(4):319-21. doi: 10.1007/BF00873047. Invest New Drugs. 1994. PMID: 7775133 Clinical Trial.

5

Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.

Weiner LM, Li W, Holmes M, Catalano RB, Dovnarsky M, Padavic K, Alpaugh RK. Weiner LM, et al. Cancer Res. 1994 Aug 1;54(15):4084-90. Cancer Res. 1994. PMID: 8033141 Clinical Trial.

6

Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum.

Coia L, Hoffman J, Scher R, Weese J, Solin L, Weiner L, Eisenberg B, Paul A, Hanks G. Coia L, et al. Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):161-7. doi: 10.1016/0360-3016(94)90531-2. Int J Radiat Oncol Biol Phys. 1994. PMID: 8083109 Clinical Trial.

7

Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1.

Weiner LM, Holmes M, Richeson A, Godwin A, Adams GP, Hsieh-Ma ST, Ring DB, Alpaugh RK. Weiner LM, et al. J Immunol. 1993 Sep 1;151(5):2877-86. J Immunol. 1993. PMID: 8103070

8

Binding characteristics and antitumor properties of 1A10 bispecific antibody recognizing gp40 and human transferrin receptor.

Amoroso AR, Clark JI, Litwin S, Hsieh-Ma S, Shi T, Alpaugh RK, Adams GP, Wolf EJ, Ring DB, Weiner LM. Amoroso AR, et al. Among authors: weiner lm. Cancer Res. 1996 Jan 1;56(1):113-20. Cancer Res. 1996. PMID: 8548750

9

Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.

Weiner LM, Clark JI, Ring DB, Alpaugh RK. Weiner LM, et al. J Hematother. 1995 Oct;4(5):453-6. doi: 10.1089/scd.1.1995.4.453. J Hematother. 1995. PMID: 8581384 Clinical Trial.

10

Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fc gamma RIII.

Weiner LM, Alpaugh RK, Amoroso AR, Adams GP, Ring DB, Barth MW. Weiner LM, et al. Cancer Immunol Immunother. 1996 Mar;42(3):141-50. doi: 10.1007/s002620050264. Cancer Immunol Immunother. 1996. PMID: 8640842 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

303 results

Search Page

Filters